Back to Journals » Clinical Interventions in Aging » Volume 11

Do fall-risk-increasing drugs have an impact on mortality in older hip fracture patients? A population-based cohort study

Authors Kragh Ekstam A, Elmstahl S

Received 4 December 2015

Accepted for publication 4 February 2016

Published 29 April 2016 Volume 2016:11 Pages 489—496


Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Supriya Swarnkar

Peer reviewer comments 4

Editor who approved publication: Dr Richard Walker

Annika Kragh Ekstam,1,2 Sölve Elmståhl1

1Division of Geriatric Medicine, Department of Health Sciences, Lund University, Skåne University Hospital, Malmö, 2Department of Medicine, Hässleholm Hospital, Hässleholm, Sweden

The aim of this study was to assess the mortality in hip fracture patients with regard to use of fall-risk-increasing drugs (FRIDs), by comparing survival in exposed and nonexposed individuals.
This was a general population-based cohort study.
Data on hip fracture patients were retrieved from three national databases.
All hip fracture patients aged 60 years or older in a Swedish county in 2006 participated in this study.
We studied the mortality in hip fracture patients by comparing those exposed to FRIDs, combinations of FRIDs, and polypharmacy to nonexposed patients, adjusting for age and sex. For survival estimates in patients using four or more FRIDs, a Cox regression analysis was used, adjusting for age, sex, and use of any four or more drugs.
First-year all-cause mortality was 24.6% (N=503) in 2,043 hip fracture patients aged 60 years or older, including 170 males (33.8%) and 333 females (66.2%). Patients prescribed four or more FRIDs, five or more drugs (polypharmacy), psychotropic drugs, and cardiovascular drugs showed significantly increased first-year mortality. Exposure to four or more FRIDs (518 patients, 25.4%) was associated with an increased mortality at 30 days with odds ratios (ORs) 2.01 (95% confidence interval [CI] 1.44–2.79), 90 days with OR 1.56 (95% CI 1.19–2.04), 180 days with OR 1.54 (95% CI 1.20–1.97), and 365 days with OR 1.43 (95% CI 1.13–1.80). Cox regression analyses adjusted for age, sex, and use of any four or more drugs showed a significantly higher mortality in patients treated with four or more FRIDs at 90 days (P=0.015) and 180 days (P=0.012) compared to patients treated with three or less FRIDs.
First-year all-cause mortality was significantly higher in older hip fracture patients exposed before the fracture to FRIDs, in particular to four or more FRIDs, polypharmacy, psychotropic, and cardiovascular drugs. Interventions aiming to optimize both safety and benefit of drug treatment for older people should include limiting the use of FRIDs.

mortality, hip fracture, fall-risk-increasing drugs, population based, older people

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]


Readers of this article also read:

Hospitalization in older patients due to adverse drug reactions – the need for a prediction tool

Parameswaran Nair N, Chalmers L, Peterson GM, Bereznicki BJ, Castelino RL, Bereznicki LR

Clinical Interventions in Aging 2016, 11:497-505

Published Date: 2 May 2016

Validity and reliability of the Persian version of the Brief Aging Perceptions Questionnaire in Iranian older adults

Sadegh Moghadam L, Foroughan M, Mohammadi Shahboulaghi F, Ahmadi F, Sajjadi M, Farhadi A

Clinical Interventions in Aging 2016, 11:507-511

Published Date: 2 May 2016

Fungistatic activity of all-trans retinoic acid against Aspergillus fumigatus and Candida albicans

Campione E, Gaziano R, Marino D, Orlandi A

Drug Design, Development and Therapy 2016, 10:1551-1555

Published Date: 29 April 2016

Participants' perception of pharmaceutical clinical research: a cross-sectional controlled study

González-Saldivar G, Rodríguez-Gutiérrez R, Viramontes-Madrid JL, Salcido-Montenegro A, Carlos-Reyna KEG, Treviño-Alvarez AM, Álvarez-Villalobos NA, González-González JG

Patient Preference and Adherence 2016, 10:727-734

Published Date: 29 April 2016

Fried frailty phenotype assessment components as applied to geriatric inpatients

Bieniek J, Wilczyński K, Szewieczek J

Clinical Interventions in Aging 2016, 11:453-459

Published Date: 22 April 2016